Back to Journals » International Journal of Nanomedicine » Volume 6

Application of hydroxyapatite nanoparticles in development of an enhanced formulation for delivering sustained release of triamcinolone acetonide

Authors Koocheki S, Madaeni, Niroomandi

Published 19 April 2011 Volume 2011:6 Pages 825—833

DOI https://doi.org/10.2147/IJN.S18045

Review by Single anonymous peer review

Peer reviewer comments 2



Saeid Koocheki1, Sayed Siavash Madaeni1, Parisa Niroomandi2
1Membrane Research Center, Chemical Engineering Department, Razi University, Kermanshah, Iran; 2Exir Pharmaceutical Co, Lorestan, Boroujerd, Iran

Abstract: We report an analysis of in vitro and in vivo drug release from an in situ formulation consisting of triamcinolone acetonide (TR) and poly(D,L-lactide-co-glycolide) (PLGA) and the additives glycofurol (GL) and hydroxyapatite nanoparticles (HA). We found that these additives enhanced drug release rate. We used the Taguchi method to predict optimum formulation variables to minimize the initial burst. This method decreased the burst rate from 8% to 1.3%. PLGA-HA acted as a strong buffer, thereby preventing tissue inflammation at the injection site caused by the acidic degradation products of PLGA. Characterization of the optimized formulation by a variety of techniques, including scanning electron microscopy, X-ray diffraction, differential scanning calorimetry, and Fourier transform near infrared spectroscopy, revealed that the crystalline structure of TR was converted to an amorphous form. Therefore, this hydrophobic agent can serve as an additive to modify drug release rates. Data generated by in vitro and in vivo experiments were in good agreement.

Keywords: triamcinolone acetonide, glycofurol, hydroxyapatite nanoparticle, PLGA

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.